313 related articles for article (PubMed ID: 26947588)
21. Proteomic changes induced by podophyllotoxin in human cervical carcinoma HeLa cells.
Wang B; Chen L; Zhen H; Zhou L; Shi P; Huang Z
Am J Chin Med; 2013; 41(1):163-75. PubMed ID: 23336514
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?
Moioli M; Papadia A; Mammoliti S; Pacella E; Menoni S; Menada MV; Ragni N
Minerva Ginecol; 2012 Apr; 64(2):95-107. PubMed ID: 22481620
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the in vitro synergistic effect of 5-fluorouracil and cisplatin on cervical carcinoma cells.
Yim EK; Lee SB; Lee KH; Kim CJ; Park JS
Int J Gynecol Cancer; 2006; 16(3):1321-9. PubMed ID: 16803524
[TBL] [Abstract][Full Text] [Related]
24. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
25. [Neoadjuvant chemotherapy with paclitaxel and cisplantin or carboplatin for patients with locally advanced uterine cervical cancer].
Zhang R; Li B; Bai P; Li HJ; Li SM; Wu LY; Li W
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):616-20. PubMed ID: 22325224
[TBL] [Abstract][Full Text] [Related]
26. [Inhibiting HSP70 expression enhances cisplatin sensitivity of cervical cancer cells].
Liu J; Liu J; Li SZ; Zheng YA; Guo SY; Wang X
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 37(4):475-481. PubMed ID: 28446399
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
28. Identification of proteomic signatures associated with lung cancer and COPD.
Pastor MD; Nogal A; Molina-Pinelo S; Meléndez R; Salinas A; González De la Peña M; Martín-Juan J; Corral J; García-Carbonero R; Carnero A; Paz-Ares L
J Proteomics; 2013 Aug; 89():227-37. PubMed ID: 23665002
[TBL] [Abstract][Full Text] [Related]
29. Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method.
Gong F; Peng X; Zeng Z; Yu M; Zhao Y; Tong A
Mol Cell Biochem; 2011 Feb; 348(1-2):141-7. PubMed ID: 21080034
[TBL] [Abstract][Full Text] [Related]
30. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.
Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111
[TBL] [Abstract][Full Text] [Related]
31. Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT.
Zhu H; Tao X; Zhou L; Sheng B; Zhu X; Zhu X
BMC Cancer; 2019 Aug; 19(1):865. PubMed ID: 31470801
[TBL] [Abstract][Full Text] [Related]
32. Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer.
Hodgkinson VC; Agarwal V; ELFadl D; Fox JN; McManus PL; Mahapatra TK; Kneeshaw PJ; Drew PJ; Lind MJ; Cawkwell L
J Proteomics; 2012 May; 75(9):2745-52. PubMed ID: 22498883
[TBL] [Abstract][Full Text] [Related]
33. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
[TBL] [Abstract][Full Text] [Related]
34. PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.
Zhu H; Wu J; Zhang W; Luo H; Shen Z; Cheng H; Zhu X
Sci Rep; 2016 Aug; 6():30788. PubMed ID: 27492148
[TBL] [Abstract][Full Text] [Related]
35. Proteomics approaches for identification of tumor relevant protein targets in pulmonary squamous cell carcinoma by 2D-DIGE-MS.
Lihong H; Linlin G; Yiping G; Yang S; Xiaoyu Q; Zhuzhu G; Xiaohan Y; Xin Z; Liyan X; Shujuan S
PLoS One; 2014; 9(4):e95121. PubMed ID: 24740010
[TBL] [Abstract][Full Text] [Related]
36. Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line.
Murphy L; Henry M; Meleady P; Clynes M; Keenan J
Biochim Biophys Acta; 2008 Sep; 1784(9):1184-91. PubMed ID: 18503785
[TBL] [Abstract][Full Text] [Related]
37. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431.
Castagna A; Antonioli P; Astner H; Hamdan M; Righetti SC; Perego P; Zunino F; Righetti PG
Proteomics; 2004 Oct; 4(10):3246-67. PubMed ID: 15378690
[TBL] [Abstract][Full Text] [Related]
38. Identification of cisplatin-resistance associated genes through proteomic analysis of human ovarian cancer cells and a cisplatin-resistant subline.
Zhou J; Wei YH; Liao MY; Xiong Y; Li JL; Cai HB
Asian Pac J Cancer Prev; 2012; 13(12):6435-9. PubMed ID: 23464471
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.
Sugiyama T; Nishida T; Hasuo Y; Fujiyoshi K; Yakushiji M
Gynecol Oncol; 1998 May; 69(2):130-6. PubMed ID: 9600820
[TBL] [Abstract][Full Text] [Related]
40. A Fifteen-Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer.
Tian X; Wang X; Cui Z; Liu J; Huang X; Shi C; Zhang M; Liu T; Du X; Li R; Huang L; Gong D; Tian R; Cao C; Jin P; Zeng Z; Pan G; Xia M; Zhang H; Luo B; Xie Y; Li X; Li T; Wu J; Zhang Q; Chen G; Hu Z
Adv Sci (Weinh); 2021 May; 8(10):2001978. PubMed ID: 34026427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
